Takao Yatsunami
Direttore/Membro del Consiglio presso Medicinal Chemistry Pharmaceutical Co. Ltd.
Profilo
Takao Yatsunami is currently a Representative Director at Medicinal Chemistry Pharmaceutical Co. Ltd.
and Medicinal Chemistry Pharmaceuticals Co. Ltd.
He was previously a Director at GeneticLab Co., Ltd.
Posizioni attive di Takao Yatsunami
Società | Posizione | Inizio |
---|---|---|
Medicinal Chemistry Pharmaceutical Co. Ltd.
Medicinal Chemistry Pharmaceutical Co. Ltd. BiotechnologyHealth Technology Part of Trans Genic Inc., Medicinal Chemistry Pharmaceutical Co. Ltd. develops antibody drugs for controlling diseases using glycol technology. The company is based in Sapporo, Japan. The Japanese company was founded in 2010 by Katsuhiko Ito. Medicinal Chemistry Pharmaceutical Co. was acquired by Trans Genic Inc. on April 22, 2020. | Direttore/Membro del Consiglio | - |
Medicinal Chemistry Pharmaceuticals Co. Ltd.
Medicinal Chemistry Pharmaceuticals Co. Ltd. BiotechnologyHealth Technology Medicinal Chemistry Pharmaceuticals Co. Ltd. is a company based in Sapporo, Japan that was founded in 2010. The Japanese company specializes in providing a monoclonal antibody-produced service made by ganp® mouse technology, which is expected to acquire high-parental and high-specific antibodies. The company offers antibody variable areas analysis, hybridoma culture, antibody refinement by affinity column chromatography, and contract services for various refined antibodies. Additionally, they provide analysis services for variable regional sequences for mouse monoclonal antibodies. The company also accepts various consultations on sugar chain synthesis and sugar chain analysis. The company's main focus is on podoplanin (PDPN), a mucin type that highly reflects on various malignant tumors such as brain tumors, oral cancer, lung cancer, esophageal cancer, malignant mild skin, ovarian cancer, cervical cancer, etc. PDPN has been revealed to enhance the infiltration and metastasis of cancer cells, and is related to cancer. | Direttore/Membro del Consiglio | - |
Precedenti posizioni note di Takao Yatsunami
Società | Posizione | Fine |
---|---|---|
GeneticLab Co., Ltd.
GeneticLab Co., Ltd. Miscellaneous Commercial ServicesCommercial Services GeneticLab Co., Ltd. provides gene expression analysis and pathological diagnostic services. It also engages in medical care development services. The company was founded on September 1, 2000 and is headquartered in Sapporo, Japan. | Direttore/Membro del Consiglio | 01/01/2022 |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
Aziende private | 3 |
---|---|
GeneticLab Co., Ltd.
GeneticLab Co., Ltd. Miscellaneous Commercial ServicesCommercial Services GeneticLab Co., Ltd. provides gene expression analysis and pathological diagnostic services. It also engages in medical care development services. The company was founded on September 1, 2000 and is headquartered in Sapporo, Japan. | Commercial Services |
Medicinal Chemistry Pharmaceutical Co. Ltd.
Medicinal Chemistry Pharmaceutical Co. Ltd. BiotechnologyHealth Technology Part of Trans Genic Inc., Medicinal Chemistry Pharmaceutical Co. Ltd. develops antibody drugs for controlling diseases using glycol technology. The company is based in Sapporo, Japan. The Japanese company was founded in 2010 by Katsuhiko Ito. Medicinal Chemistry Pharmaceutical Co. was acquired by Trans Genic Inc. on April 22, 2020. | Health Technology |
Medicinal Chemistry Pharmaceuticals Co. Ltd.
Medicinal Chemistry Pharmaceuticals Co. Ltd. BiotechnologyHealth Technology Medicinal Chemistry Pharmaceuticals Co. Ltd. is a company based in Sapporo, Japan that was founded in 2010. The Japanese company specializes in providing a monoclonal antibody-produced service made by ganp® mouse technology, which is expected to acquire high-parental and high-specific antibodies. The company offers antibody variable areas analysis, hybridoma culture, antibody refinement by affinity column chromatography, and contract services for various refined antibodies. Additionally, they provide analysis services for variable regional sequences for mouse monoclonal antibodies. The company also accepts various consultations on sugar chain synthesis and sugar chain analysis. The company's main focus is on podoplanin (PDPN), a mucin type that highly reflects on various malignant tumors such as brain tumors, oral cancer, lung cancer, esophageal cancer, malignant mild skin, ovarian cancer, cervical cancer, etc. PDPN has been revealed to enhance the infiltration and metastasis of cancer cells, and is related to cancer. | Health Technology |
- Borsa valori
- Insiders
- Takao Yatsunami